Halesha Basavarajappa - Publications

Indiana University School of Medicine, Indianapolis, IN, United States 

13 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Schwikkard S, Whitmore H, Sishtla K, Sulaiman RS, Shetty T, Basavarajappa HD, Waller C, Alqahtani A, Frankemoelle L, Chapman A, Crouch N, Wetschnig W, Knirsch W, Andriantiana J, Mas-Claret E, et al. The Antiangiogenic Activity of Naturally Occurring and Synthetic Homoisoflavonoids from the Hyacinthaceae ( sensu APGII). Journal of Natural Products. PMID 30951308 DOI: 10.1021/Acs.Jnatprod.8B00989  1
2017 Basavarajappa HD, Sulaiman RS, Qi X, Shetty T, Sheik Pran Babu S, Sishtla KL, Lee B, Quigley J, Alkhairy S, Briggs CM, Gupta K, Tang B, Shadmand M, Grant MB, Boulton ME, et al. Ferrochelatase is a therapeutic target for ocular neovascularization. Embo Molecular Medicine. PMID 28377496 DOI: 10.15252/Emmm.201606561  1
2016 Lee B, Sun W, Lee H, Basavarajappa H, Sulaiman RS, Sishtla K, Fei X, Corson TW, Seo SY. Design, synthesis and biological evaluation of photoaffinity probes of antiangiogenic homoisoflavonoids. Bioorganic & Medicinal Chemistry Letters. PMID 27481561 DOI: 10.1016/J.Bmcl.2016.07.043  0.44
2015 Basavarajappa HD, Lee B, Lee H, Sulaiman RS, An H, Magaña C, Shadmand M, Vayl A, Rajashekhar G, Kim EY, Suh YG, Lee K, Seo SY, Corson TW. Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization. Journal of Medicinal Chemistry. 58: 5015-27. PMID 26035340 DOI: 10.1021/Acs.Jmedchem.5B00449  0.44
2015 Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sheikh MG, Rane R, Basu R, Verma P, Sundaram A, Mukherjee K, de Sousa SM. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase. Journal of Biomolecular Screening. 20: 265-74. PMID 25300873 DOI: 10.1177/1087057114554170  0.44
2014 Sulaiman RS, Basavarajappa HD, Corson TW. Natural product inhibitors of ocular angiogenesis. Experimental Eye Research. 129: 161-71. PMID 25304218 DOI: 10.1016/J.Exer.2014.10.002  1
2014 Lee B, Basavarajappa HD, Sulaiman RS, Fei X, Seo SY, Corson TW. The first synthesis of the antiangiogenic homoisoflavanone, cremastranone. Organic & Biomolecular Chemistry. 12: 7673-7. PMID 25167470 DOI: 10.1039/C4Ob01604A  0.44
2014 Basavarajappa HD, Lee B, Fei X, Lim D, Callaghan B, Mund JA, Case J, Rajashekhar G, Seo SY, Corson TW. Synthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growth. Plos One. 9: e95694. PMID 24752613 DOI: 10.1371/Journal.Pone.0095694  0.44
2014 Thériault BL, Basavarajappa HD, Lim H, Pajovic S, Gallie BL, Corson TW. Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer. Plos One. 9: e91540. PMID 24626475 DOI: 10.1371/Journal.Pone.0091540  1
2014 Kale RR, Kale MG, Waterson D, Raichurkar A, Hameed SP, Manjunatha MR, Kishore Reddy BK, Malolanarasimhan K, Shinde V, Koushik K, Jena LK, Menasinakai S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, et al. Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. Bioorganic & Medicinal Chemistry Letters. 24: 870-9. PMID 24405701 DOI: 10.1016/J.Bmcl.2013.12.080  0.44
2013 Kale MG, Raichurkar A, P SH, Waterson D, McKinney D, Manjunatha MR, Kranthi U, Koushik K, Jena Lk, Shinde V, Rudrapatna S, Barde S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, et al. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. Journal of Medicinal Chemistry. 56: 8834-48. PMID 24088190 DOI: 10.1021/Jm401268F  0.44
2013 Shirude PS, Madhavapeddi P, Tucker JA, Murugan K, Patil V, Basavarajappa H, Raichurkar AV, Humnabadkar V, Hussein S, Sharma S, Ramya VK, Narayan CB, Balganesh TS, Sambandamurthy VK. Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis. Acs Chemical Biology. 8: 519-23. PMID 23268609 DOI: 10.1021/Cb300510W  0.44
2012 Basavarajappa HD, Corson TW. KIF14 as an oncogene in retinoblastoma: a target for novel therapeutics? Future Medicinal Chemistry. 4: 2149-52. PMID 23190103 DOI: 10.4155/Fmc.12.158  1
Show low-probability matches.